Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.

Toxicology letters - 5 Jan 2015

Vredenburg Galvin, den Braver-Sewradj Shalenie, van Vugt-Lussenburg Barbara M A, Vermeulen Nico P E, Commandeur Jan N M, Vos J Chris

Abstract excerpt

Cyclophosphamide (CPA) and ifosfamide (IFA) are widely used anticancer agents that require metabolic activation by cytochrome P450 (CYP) enzymes. While 4-hydroxylation yields DNA-alkylating and cytotoxic metabolites, N-dechloroethylation results in the generation of neuro- and nephrotoxic byprodu...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Bone Neoplasms
Share to Cell Survival

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cyclophosphamide

Share to Cytochrome P-450 CYP2B6

Share to Hydroxylation

Share to Microsomes, Liver

Share to Osteosarcoma

Source

Identifiers

PMID: 25448283
DOI: 10.1016/j.toxlet.2014.11.005

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25448283-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Activation of the anticancer drugs cyclophosphamide and ifosfamide by cytochrome P450 BM3 mutants.PMID 25448283Read ↗

Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics.Semantic proximity Read ↗

Evaluation of alkoxyresorufins as fluorescent substrates for cytochrome P450 BM3 and site-directed mutants.Semantic proximity Read ↗

Application of engineered cytochrome P450 mutants as biocatalysts for the synthesis of benzylic and aromatic metabolites of fenamic acid NSAIDs.Semantic proximity Read ↗

Synthesis of cyclophosphamide metabolites by a peroxygenase from Marasmius rotula for toxicological studies on human cancer cellsSemantic proximity Read ↗

Application of drug metabolising mutants of cytochrome P450 BM3 (CYP102A1) as biocatalysts for the generation of reactive metabolites.Semantic proximity Read ↗

Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-Km catalysts of cyclophosphamide and ifosfamide activation.Semantic proximity Read ↗

Selective ALDH3A1 inhibition by benzimidazole analogues increase mafosfamide sensitivity in cancer cells.Semantic proximity Read ↗

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity Read ↗

Application of a Continuous-Flow Bioassay to Investigate the Organic Solvent Tolerability of Cytochrome P450 BM3 Mutants.Semantic proximity Read ↗

Role of CYP2B6 and CYP3A4 in the In Vitro N-Dechloroethylation of (R)- and (S)-Ifosfamide in Human Liver MicrosomesSemantic proximity Read ↗

The role of cytochrome P450 in cytotoxic bioactivation: future therapeutic directions.Semantic proximity Read ↗

Generation, validation, and application of a P450 homology model.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.